Effect of Tocotrienols enriched canola oil on glycemic control and oxidative status in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled clinical trial
Vafa M, Haghighat N, Moslehi N, Eghtesadi S, Heydari I
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 26 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2015-01-01 · J Res Med Sci · vol. 20 · número 6 · pág. 540
- Editorial
- Medknow
- Citado
- 34 citas · más que el 83% de estudios similares · 1.8× el promedio de su campo
- Referencias
- 42 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-SA
- Áreas de investigación
- Antioxidant Activity and Oxidative Stress · Coconut Research and Applications · Fatty Acid Research and Health
- Palabras clave
- Medicine, Canola, Glycemic, Malondialdehyde, Internal medicine, Placebo, Diabetes mellitus, Insulin resistance, Vitamin E, Type 2 diabetes, Type 2 Diabetes Mellitus, Insulin, Endocrinology, Gastroenterology, Oxidative stress, Antioxidant, Food science, Biochemistry, Chemistry
5 autores
- Mohammadreza Vafa🇮🇷Iran University of Medical Sciences
- Neda Haghighat🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Nazanin Moslehi🇮🇷Research Institute for Endocrine Sciences; Shahid Beheshti University of Medical Sciences
- Shahriar Eghtesadi🇮🇷Iran University of Medical Sciences
- Iraj Heydari🇮🇷Iran University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Tocotrienols have been shown to improve glycemic control and redox balance in an animal study, but their effects on patients with diabetes are unknown. The study aimed to investigate whether tocotrienols improves glycemic control, insulin sensitivity, and oxidative stress in individuals with type 2 diabetes mellitus (T2DM).
Materials and methods
This study was a double-blinded, placebo-controlled, randomized trial. A total of 50 patients, aged 35-60 years, with T2DM treated by noninsulin hypoglycemic drugs were randomly assigned to receive either 15 mL/day tocotrienols (200 mg) enriched canola oil (n = 25) or pure canola oil (n = 25) for 8 weeks. Fasting blood sugar (FBS), fasting insulin, total antioxidant capacity (TAC), malondialdehyde (MDA), and homeostatic model assessment for insulin resistance (HOMA-IR) were determined before and after the intervention. The data were compared between and within groups, before and after the intervention.
Results
Baseline characteristics of participants including age, sex, physical activity, disease duration, and type of drug consumption were not significantly different between the two groups. In tocotrienol enriched canola oil, FBS (mean percent change: -15.4% vs. 3.9%; P = 0.006) and MDA (median percent change: -35.6% vs. 16.3%; P = 0.003) were significantly reduced while TAC was significantly increased (median percent change: 21.4% vs. 2.3%; P = 0.001) compared to pure canola oil. At the end of the study, patients who treated with tocotrienols had lower FBS (P = 0.023) and MDA (P = 0.044) compared to the pure canola oil group. However, tocotrienols had no effect on insulin concentrations and HOMA-IR.
Conclusion
Tocotrienols can improve FBS concentrations and modifies redox balance in T2DM patients with poor glycemic control and can be considered in combination with hypoglycemic drugs to better control of T2DM.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-SA).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.